8-KShareholder Matters

AbbVie Inc. 8-K Report, Shareholder Vote Results (May 10, 2016)

Filed May 10, 2016For Securities:ABBV

Summary

This 8-K filing from AbbVie Inc. reports on the outcomes of its Annual Meeting of Stockholders held on May 6, 2016. The key information for investors centers on the voting results for director elections, ratification of the independent auditor, executive compensation, and several stockholder proposals. The company's management proposals, including the election of Class I Directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2016, received overwhelming support from shareholders. While executive compensation was approved on an advisory basis, two significant stockholder proposals – one regarding a drug disposal report and another concerning a lobbying report – were not approved by the majority of shareholders. These voting outcomes reflect shareholder confidence in the current board and auditing firm, while also indicating a divergence of opinion on specific corporate social responsibility initiatives.

Key Highlights

  • 1AbbVie Inc. held its Annual Meeting of Stockholders on May 6, 2016.
  • 2Stockholders overwhelmingly re-elected AbbVie's Class I Directors for terms expiring in 2019.
  • 3Ernst & Young LLP was ratified as AbbVie's independent registered public accounting firm for 2016 with substantial approval.
  • 4The compensation of AbbVie's named executive officers was approved on an advisory basis.
  • 5A management proposal regarding the annual election of directors was approved by a significant majority.
  • 6A stockholder proposal requesting a drug disposal report was not approved.
  • 7A stockholder proposal requesting a lobbying report was also not approved.

Frequently Asked Questions

The primary outcomes included the re-election of Class I Directors, the ratification of Ernst & Young LLP as the independent auditor for 2016, advisory approval of executive compensation, and the outcome of several stockholder proposals. Most management proposals were approved, while two significant stockholder proposals concerning drug disposal and lobbying reports were not.

The election of AbbVie's Class I Directors for terms expiring in 2019 received very strong support, with the vast majority of votes cast 'For' their election. This indicates shareholder confidence in the current board members.

Yes, two stockholder proposals did not receive majority approval. These were a proposal requesting a report on drug disposal and a proposal requesting a report on lobbying activities. This suggests that shareholders, in aggregate, did not support these specific initiatives at this time.

The ratification of Ernst & Young LLP as the independent registered public accounting firm for 2016 is a routine but important vote. Strong approval signifies shareholder confidence in the integrity and independence of the company's financial audits, which is crucial for investor trust.